Journal article
Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT
- Abstract:
-
Background
Although biological therapies have transformed the outlook for those with rheumatoid arthritis, there is a lack of any meaningful response in approximately 40% of patients. The role of B cells in rheumatoid arthritis pathogenesis is well recognised and is supported by the clinical efficacy of the B-cell-depleting agent rituximab (MabThera, F. Hoffman La-Roche Ltd, Basel, Switzerland). Rituximab is licensed for use in rheumatoid arthritis following failure of... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 10.0MB, Terms of use)
-
- Publisher copy:
- 10.3310/GOPL1729
Authors
- Publisher:
- NIHR Journals Library
- Journal:
- Efficacy and Mechanism Evaluation More from this journal
- Volume:
- 9
- Issue:
- 7
- Publication date:
- 2022-08-22
- DOI:
- EISSN:
-
2050-4373
- ISSN:
-
2050-4365
- Pmid:
-
36001738
- Language:
-
English
- Keywords:
- Pubs id:
-
1278036
- Local pid:
-
pubs:1278036
- Deposit date:
-
2022-11-18
Terms of use
- Copyright holder:
- Queen’s Printer and Controller of HMSO
- Copyright date:
- 2022
- Rights statement:
- © Queen’s Printer and Controller of HMSO 2022. This work was produced by Humby et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.
If you are the owner of this record, you can report an update to it here: Report update to this record